Ichida Lab creates in vitro models of human neurodegenerative diseases by converting patients’ skin fibroblasts into disease-affected neural cells. This enables them to screen thousands of drug-like compounds in search of potential therapeutics that slow or stop the degeneration of these cells in petri dishes — and eventually in patients.Read More
Icagen is an integrated early discovery partner, offering clients specialized technologies and deep scientific expertise to solve myriad challenges and optimize efficiency moving from target to lead. We work in multi-year, integrated programs, as well as individual projects to fill gaps in R&D efforts.Read More
AcuraStem offers the best in class human model of the form of ALS caused by the C9ORF72 mutation. Cerion used our model in addition to a mouse model to prove preclinical in vitro efficacy. AcuraStem uniquely enabled preclinical efficacy testing in disease relevant human cells. Read more about the work here:Read More
Established in 2012 by Governor Brown, GO-Biz serves as California’s single point of contact for economic development and job creation efforts, offering a range of services to business owners including: attraction, retention and expansion services, permit streamlining, regulatory assistance, business assistance, international trade dev., assistance with state gvmt., etc.Read More
Keiretsu’s worldwide network is extensive and includes 52 chapters on 3 continents. Members invest in high-quality, diverse opportunities, and are ranked as the most active venture investors in the USA.Read More
At AcuraStem, we employ the latest scientific breakthroughs to inform our best-in-class technology platform, in which complex cellular models from ALS patient cells and sophisticated assays permit our scientists to model patient tissues in the laboratory. Using this advanced platform, we can evaluate the progression of ALS and test combinations of therapeutic approaches to find the most efficacious treatments possible. AcuraStem has leveraged this platform to identify a novel ALS target and preclinical lead candidate which we are advancing to the clinic. AcuraStem is providing access to this technology platform to commercial and academic partners so that they can evaluate their therapeutic candidates under development.
AcuraStem is currently accepting seed stage funds to more rapidly progress our promising lead small molecule for ALS, and also scale our in vitro pharmacological profiling service for biopharmaceutical companies with their own ALS research programs. If you are interested in being an early stage investor in AcuraStem, please contact us.
Acurastem'S Patient RegistRY